Rosetta Genomics Granted U.S. Patent Allowance

Rosetta Genomics Granted U.S. Patent Allowance 
Covers Methods of Use and Composition of Matter for Diagnosing Risk
and Treatment Planning for Preeclampsia 
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 09/12/13 -- 
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces that the
U.S. Patent and Trademark Office granted the Company a Notice of
Allowance in connection with U.S. Patent Application Number
12/864,424, titled "Methods and Compositions for Diagnosing
Complications of Pregnancy."  
The claims in the patent allowance refer to a method of use and
composition of matter for determining the risk of developing
preeclampsia and the development of a treatment strategy based on the
expression of a microRNA known as microRNA-122a, or miR-122a. 
"Preeclampsia is a serious condition that affects 3-5% of all
pregnancies and contributes significantly to increased morbidity and
mortality in both mothers and babies. Given the challenges of
clinical recognition and the magnitude of impact when preeclampsia
goes untreated, improved early diagnosis is vital to improve outcomes
of pregnancy," noted E. Robert Wassman, MD, FAAP, FACMG, Rosetta
Genomics' Chief Medical Officer. "In my experience, the reproductive
field has been keenly feeling this unmet need, and to date all
attempts to resolve this diagnostic and therapeutic challenge remain
"We continue to pursue patent protection for our intellectual
property and are pleased to receive this new patent allowance in
obstetrics. Preeclampsia is a major cause of maternal, fetal and
neonatal morbidity and mortality, and it continues to be one of the
great challenges in obstetrics. A screening test in early pregnancy
that identifies women at risk of developing preeclampsia would allow
obstetricians to commence prophylactic treatments, and instigate
high-risk surveillance protocols," stated Kenneth A. Berlin,
President and Chief Executive Officer of Rosetta Genomics. "We remain
committed to executing our intellectual property strategy and to
expanding our leadership position in microRNA technology as it
protects our current products, provides the foundation for new
product development and offers multiple opportunities for potential
development partnerships as well as transactions to monetize IP."  
Rosetta's robust patent portfolio includes 32 issued patents,
including 28 in the U.S. In addition, Rosetta has 44 patent
applications pending, of which 25 are in the U.S. 
About Rosetta Cancer Testing Services (formerly the miRview(R)
product line)
 Rosetta Cancer Tests are a series of microRNA-based
diagnostic testing services offered by Rosetta Genomics. The Rosetta
Cancer Origin Test(TM) can accurately identify the primary tumor type
in primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). Rosetta Mesothelioma Test(TM) diagnoses
mesothelioma, a cancer connected to asbestos exposure. The Rosetta
Lung Cancer Test(TM) accurately identifies the four main subtypes of
lung cancer using small amounts of tumor cells. The Rosetta Kidney
Cancer Test(TM) accurately classifies the four most common kidney
tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. Rosetta's assays are designed to
provide objective diagnostic data; it is the treating physician's
responsibility to diagnose and administer the appropriate treatment.
In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a
year may benefit from the Rosetta Cancer Origin Test(TM), 60,000 from
the Rosetta Mesothelioma Test(TM), 65,000 from the Rosetta Kidney
Cancer Test(TM) and 226,000 patients from the Rosetta Lung Cancer
Test(TM). The Company's assays are offered directly by Rosetta
Genomics in the U.S., and through distributors around the world. For
more information, please visit Parties
interested in ordering the test can contact Rosetta Genomics at (215)
382-9000 ext. 309. 
About Rosetta Genomics
 Rosetta develops and commercializes a full
range of microRNA-based molecular diagnostics. Founded in 2000,
Rosetta's integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building on
its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools. Rosetta's cancer testing services are commercially
available through its Philadelphia-based CAP-accredited,
CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with
the 2012 North American Next Generation Diagnostics Entrepreneurial
Company of the Year Award. 
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test, Rosetta pursuing any product or service in the field of
preeclampsia either on its own or via partnership, improving the
ability of physicians to accurately diagnose CUP, the growth in
number of samples being processed and billed at Rosetta's CLIA lab,
Rosetta's development or commercialization of molecular diagnostics,
the market acceptance of Rosetta's cancer testing services,
particularly the Rosetta Cancer Origin Test(TM), Rosetta's
capitalization of its microRNA platform, Rosetta's patent position
and Rosetta's development of personalized medicine products and
services constitute forward-looking statements for the purposes of
the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various
important factors, including those risks more fully discussed in the
"Risk Factors" section of Rosetta's Annual Report on Form 20-F for
the year ended December 31, 2012 as filed with the SEC. In addition,
any forward-looking statements represent Rosetta's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless
required by law. 
Company Contact: 
Rosetta Genomics 
Ken Berlin
President & CEO 
(215) 382-9000, ext. 326 
Investor Contacts: 
Anne Marie Fields
(212) 838-3777
Bruce Voss
(310) 691-7100 
Press spacebar to pause and continue. Press esc to stop.